The Cocktail Report Summary (sound really smart with your friends):
GLP-1 drugs (Ozempic, Wegovy, Mounjaro, Zepbound) were built for blood sugar and weight loss — but are now generating clinical evidence across at least a dozen unrelated conditions.
Semaglutide reduced major cardiovascular events by 20% in overweight adults with heart disease; the FDA approved it for cardiovascular risk in March 2024.
A study of 600,000 veterans found GLP-1 use was linked to a 14% lower risk of developing alcohol, cannabis, cocaine, nicotine, and opioid use disorders.
The drugs appear to reduce systemic inflammation — a mechanism that may explain benefits in arthritis, asthma, liver disease, and potentially cancer.
Critical caveat: most benefits fade when the drug is stopped, and a new BMJ study shows even a short break significantly raises the risk of heart attack, stroke, and death.
If you have been following the longevity space, you already know GLP-1 drugs are rewriting the rules of metabolic medicine. What is becoming clear now — from clinical trials, FDA approvals, and real-world data involving hundreds of millions of patients — is that their reach extends far beyond metabolism.
Doctors started noticing it informally. Patients on Ozempic for weight loss were reporting that decades-old joint pain had vanished, blood pressure was dropping, and sleep apnea was improving.
“There’s no weight loss — but they are getting these dramatic anti-inflammatory effects,” said Daniel Drucker, an endocrinologist at the University of Toronto who has studied GLP-1s for decades.
GLP-1s (glucagon-like peptide-1 receptor agonists — a class of drugs that mimic a naturally occurring gut hormone to regulate blood sugar and signal fullness) appear to do far more than suppress appetite. They interact with receptors throughout the body — in the gut, the heart, the kidneys, and critically, in the brain’s reward and immune pathways.
The evidence base is now substantial. A landmark trial of 3,500 patients stopped early because semaglutide so dramatically reduced kidney complications that it was considered unethical to withhold it from the placebo group.
The FDA approved Ozempic for chronic kidney disease in January 2025.
That same anti-inflammatory mechanism is showing up in unexpected places. A randomized trial found semaglutide reduced knee osteoarthritis pain versus placebo, and a 60,000-patient UK study found GLP-1 users with obesity had better control of asthma symptoms.
A study of more than 101 million patients found those on GLP-1 drugs had a markedly reduced risk of colon cancer — a finding researchers called worthy of urgent further study.
This matters directly if you are thinking about longevity: inflammation is now understood to be a root driver of nearly every major age-related disease — cardiovascular disease, neurodegeneration, cancer, metabolic dysfunction. A drug class that systemically dials down inflammation could become one of the most important longevity tools in the next decade.
The brain findings are particularly striking — and still evolving. A study of nearly 2.5 million VA patients found GLP-1 users had lower relative risk of developing dementia.
But Novo Nordisk’s two largest gold-standard trials showed semaglutide provided no cognitive benefit in patients who already had mild cognitive impairment. The working theory: the drugs may need to be taken before symptoms develop, not after.
The addiction findings may be the most surprising of all. GLP-1 receptors exist in the brain’s dopamine reward pathways — the same system that drives craving and compulsive behavior — and a BMJ study of 600,000 veterans found GLP-1 use was associated with a 14% lower risk across five substance use disorders.
A separate JAMA Psychiatry trial found patients with alcohol use disorder drank less and had fewer cravings over nine weeks on semaglutide.
The risks are real and should not be minimized. Reported complications include stomach paralysis (a condition where the stomach stops moving food properly), a rare eye disorder that can threaten vision, and a recently reported link to osteoporosis and tendon tears.
Most benefits also fade when the drug is stopped — and a new BMJ Medicine study shows that stopping even briefly significantly raises the risk of heart attack, stroke, and death.
“GLP-1s are forcing scientists to rethink what a single drug can do,” the Washington Post concluded. That is not hype — it is now the consensus view of researchers across endocrinology, cardiology, nephrology, neurology, and oncology.
Why Should You Care?
You do not need to be obese or diabetic for this research to be relevant. What GLP-1 drugs are revealing is a biological architecture — the deep connections between metabolic health, inflammation, brain chemistry, and longevity — that affects everyone.
Whether or not these drugs become part of your own health strategy, understanding what they are teaching medicine about how the body ages and fails is foundational knowledge for anyone serious about living longer and living well. The era of treating diseases as isolated systems is ending.
Source: Bernstein, L., McGinley, L., Blakemore, E., et al. “13 Surprising Ways GLP-1s May Benefit the Body, According to Science.” The Washington Post, March 27, 2026.
Enjoyed this article? Forward it to a friend who's interested in living better, longer:
